# Diencephalic Syndrome: Clinical Features, Pathophysiology, and Long-Term Outcomes

## TL;DR

Diencephalic syndrome is a rare childhood condition causing severe weight loss despite normal appetite, often linked to brain tumors and leading to long-term health issues.

## Contribution

This paper provides a comprehensive review of diencephalic syndrome's clinical features, pathophysiology, and outcomes, emphasizing the need for early diagnosis and multidisciplinary care.

## Key findings

- DS is characterized by profound weight loss, normal appetite, and visual pathway involvement in infants under 12 months.
- Low-grade gliomas, especially pilocytic astrocytomas, are the primary pathology in DS.
- Early diagnosis and chemotherapy improve survival but do not prevent long-term complications like visual impairment and hypothalamic obesity.

## Abstract

Background/Objectives: Diencephalic syndrome (DS) is an uncommon pediatric disorder presenting with severe failure to thrive despite adequate caloric intake and preserved linear growth. First characterized by Russell, this condition predominantly affects infants under 12 months and remains diagnostically challenging. Methods: We performed a comprehensive literature review examining clinical presentation, underlying pathophysiology, associated pathology, diagnostic approaches, and long-term outcomes of DS. Results: DS typically manifests in the first year of life with profound cachexia, normal or increased appetite, preserved height velocity, and characteristic features including hyperactivity, euphorism, and visual pathway involvement. Low-grade gliomas of the hypothalamic–chiasmatic region, particularly pilocytic astrocytomas, represent the predominant underlying pathology. The pathophysiological mechanisms remain incompletely understood but likely involve complex dysregulation of hypothalamic energy homeostasis. While overall survival exceeds 90% at five years, most patients experience significant long-term morbidity including visual impairment, multiple endocrine deficiencies, and hypothalamic obesity. Diagnostic delays averaging 11 months contribute to irreversible complications. Conclusions: Early recognition of DS is essential to prevent permanent visual loss and optimize outcomes. Multidisciplinary management incorporating chemotherapy as first-line treatment for underlying gliomas has improved survival while reducing radiation-associated toxicities. However, survivors face substantial lifelong sequelae requiring comprehensive monitoring and intervention. Future research should focus on elucidating precise pathophysiological mechanisms, developing targeted molecular therapies, and improving management of hypothalamic obesity and other late effects.